Quince Therapeutics, based in South San Francisco, develops therapeutics using its AIDE technology to encapsulate drugs in patients' red blood cells, targeting rare diseases like Ataxia-Telangiectasia. The company went public on May 9, 2019, and employs 32 people.
Quince Therapeutics (QNCX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Quince Therapeutics's actual EPS was -$0.34, missing the estimate of -$0.23 per share, resulting in a -46.49% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
